Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 86.55% | 59.70% | -1.45% | -17.00% | -26.82% |
| Gross Profit | -86.55% | -59.70% | 6.27% | 17.00% | 11.74% |
| SG&A Expenses | 41.23% | 137.95% | -29.06% | -69.64% | 7.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.15% | 100.00% | -12.48% | -36.85% | -13.71% |
| Operating Income | -65.15% | -100.00% | 15.37% | 36.85% | 3.44% |
| Income Before Tax | -73.20% | -103.13% | 17.45% | 41.33% | 6.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.20% | -111.16% | 17.49% | 41.36% | 6.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.20% | -111.16% | 17.49% | 41.36% | 6.57% |
| EBIT | -65.15% | -100.00% | 15.37% | 36.85% | 3.44% |
| EBITDA | -68.56% | -104.01% | 14.20% | 36.81% | 1.55% |
| EPS Basic | -36.31% | -2.27% | 60.08% | 71.66% | 43.13% |
| Normalized Basic EPS | -36.32% | 1.62% | 60.06% | 71.64% | 43.10% |
| EPS Diluted | -36.31% | -2.27% | 60.08% | 71.66% | 43.13% |
| Normalized Diluted EPS | -36.32% | 1.62% | 60.06% | 71.64% | 43.10% |
| Average Basic Shares Outstanding | 27.06% | 106.48% | 106.69% | 106.93% | 64.30% |
| Average Diluted Shares Outstanding | 27.06% | 106.48% | 106.69% | 106.93% | 64.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |